We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: GLP-1 receptor agonist
MedXY News
EnglishTag

GLP-1 receptor agonist

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Comparative Efficacy and Safety of Bofanglutide versus Semaglutide in Chinese Patients with Type 2 Diabetes: Insights from a Phase 2b Trial
Diabetes & EndocrinologysemaglutideGLP-1 receptor agonist

Comparative Efficacy and Safety of Bofanglutide versus Semaglutide in Chinese Patients with Type 2 Diabetes: Insights from a Phase 2b Trial

By MedXY|Aug 27, 2026

This phase 2b trial evaluates bofanglutide’s efficacy and safety compared to semaglutide in Chinese patients with type 2 diabetes, showing notable HbA1c reductions and manageable gastrointestinal side effects.

Long-term Safety of Oral Orforglipron in Japanese Patients with Type 2 Diabetes (ACHIEVE-J): A Multicenter, Randomized, Open-label, Phase 3 Trial
Diabetes & Endocrinology
GLP-1 receptor agonist
orforglipron

Long-term Safety of Oral Orforglipron in Japanese Patients with Type 2 Diabetes (ACHIEVE-J): A Multicenter, Randomized, Open-label, Phase 3 Trial

By MedXY|Aug 18, 2026

This phase 3 trial evaluates the 52-week safety of oral orforglipron in Japanese adults with type 2 diabetes, showing an acceptable safety profile when used alongside diet, exercise, and oral antihyperglycemic drugs.

Semaglutide as an Effective Add-On Therapy in Latent Autoimmune Diabetes in Adults: Enhancing Glycemic Control and Preserving β-Cell Function
Diabetes & EndocrinologyGLP-1 receptor agonistGlycemic Control

Semaglutide as an Effective Add-On Therapy in Latent Autoimmune Diabetes in Adults: Enhancing Glycemic Control and Preserving β-Cell Function

By MedXY|Jun 27, 2026

This study evaluates the clinical benefits of semaglutide, a GLP-1 receptor agonist, as an add-on therapy to insulin in patients with LADA, demonstrating improved glycemic control, BMI reduction, and insulin dose sparing, especially in thos

Semaglutide and Neovascular Age-Related Macular Degeneration Among Adults with Type 2 Diabetes: An OHDSI Network Study
Diabetes & EndocrinologyGLP-1 receptor agonistneovascular age-related macular degeneration

Semaglutide and Neovascular Age-Related Macular Degeneration Among Adults with Type 2 Diabetes: An OHDSI Network Study

By MedXY|Jun 10, 2026

In a large OHDSI network study of adults with type 2 diabetes, semaglutide was not associated with a higher or lower risk of neovascular age-related macular degeneration.

GLP-1 Receptor Agonist Use Linked to Lower Risk of Brain Aneurysm Rupture and Less Severe Bleeding
NeurologyChảy máu dưới nhện nãoGLP-1 receptor agonist

GLP-1 Receptor Agonist Use Linked to Lower Risk of Brain Aneurysm Rupture and Less Severe Bleeding

By MedXY|May 26, 2026

A large real-world study found GLP-1 receptor agonist use was linked to a lower risk of intracranial aneurysm rupture and milder bleeding severity if rupture occurred.

Semaglutide Reduced Effort Discounting and Improved Motivation Signals in Major Depressive Disorder
Diabetes & EndocrinologyGLP-1 receptor agonistmajor depressive disorder

Semaglutide Reduced Effort Discounting and Improved Motivation Signals in Major Depressive Disorder

By MedXY|May 5, 2026

In a 16-week randomized trial, adjunctive oral semaglutide improved effort-based decision-making in adults with major depressive disorder and overweight or obesity, suggesting a potential role for GLP-1 receptor agonism in reward-related dy

Combination Therapy with GLP-1 Receptor Agonists and SGLT-2 Inhibitors Reduces Liver and Cardiovascular Risks in MASLD and Type 2 Diabetes
Diabetes & EndocrinologyGLP-1 receptor agonistMASLD

Combination Therapy with GLP-1 Receptor Agonists and SGLT-2 Inhibitors Reduces Liver and Cardiovascular Risks in MASLD and Type 2 Diabetes

By MedXY|Apr 25, 2026

A study reveals that combining GLP-1 receptor agonists with SGLT-2 inhibitors significantly lowers the risk of major adverse liver and cardiovascular outcomes in patients with MASLD and type 2 diabetes compared to monotherapy.

Orforglipron in Type 2 Diabetes and Obesity: A Promising Oral GLP‑1 Agonist That Delivers Clinically Meaningful Weight and Glycaemic Benefits
Diabetes & EndocrinologyGLP-1 receptor agonistobesity

Orforglipron in Type 2 Diabetes and Obesity: A Promising Oral GLP‑1 Agonist That Delivers Clinically Meaningful Weight and Glycaemic Benefits

By MedXY|Nov 28, 2025

In ATTAIN‑2, oral orforglipron produced dose‑dependent, statistically superior weight loss and improved HbA1c versus placebo over 72 weeks in adults with overweight/obesity and type 2 diabetes, with an adverse‑event profile dominated by gas

Increased Gestational Weight Gain and Adverse Pregnancy Outcomes After Stopping GLP‑1 Receptor Agonists Prior to or in Early Pregnancy
Diabetes & EndocrinologyGestational Diabetesgestational weight gain

Increased Gestational Weight Gain and Adverse Pregnancy Outcomes After Stopping GLP‑1 Receptor Agonists Prior to or in Early Pregnancy

By MedXY|Nov 24, 2025

In a large retrospective cohort, women who discontinued GLP‑1 receptor agonists shortly before or during early pregnancy had greater gestational weight gain and higher risks of preterm birth, gestational diabetes, and hypertensive disorders

Targeting Mitochondria: A Practical Algorithm for Diabetes Care in Maternally Inherited Diabetes and Deafness (MIDD)
Diabetes & EndocrinologyGLP-1 receptor agonistSGLT2 inhibitor

Targeting Mitochondria: A Practical Algorithm for Diabetes Care in Maternally Inherited Diabetes and Deafness (MIDD)

By MedXY|Nov 4, 2025

Maternally inherited diabetes and deafness (MIDD) is driven by m.3243A>G mitochondrial mutation with mixed β‑cell failure and insulin resistance. GLP‑1 receptor agonists and SGLT2 inhibitors have biologic plausibility and cardiorenal ben

Tirzepatide Shows Promising Efficacy and Safety in Managing Youth-Onset Type 2 Diabetes: Insights from the SURPASS-PEDS Trial
Diabetes & EndocrinologyGLP-1 receptor agonistpediatric endocrinology

Tirzepatide Shows Promising Efficacy and Safety in Managing Youth-Onset Type 2 Diabetes: Insights from the SURPASS-PEDS Trial

By MedXY|Oct 10, 2025

The phase 3 SURPASS-PEDS trial demonstrates that tirzepatide significantly improves glycaemic control and reduces BMI in children and adolescents with type 2 diabetes, with a safety profile consistent with adult studies.

Orforglipron: A Promising Oral GLP-1 Receptor Agonist for Long-Term Obesity Management
Diabetes & Endocrinologyclinical trialGLP-1 receptor agonist

Orforglipron: A Promising Oral GLP-1 Receptor Agonist for Long-Term Obesity Management

By MedXY|Oct 9, 2025

Orforglipron, a novel oral GLP-1 receptor agonist, demonstrated significant and sustained weight reduction in obese adults without diabetes in a 72-week phase 3 trial, with a tolerable safety profile consistent with existing GLP-1 therapies

Orforglipron: A Promising Oral Small-Molecule GLP-1 Receptor Agonist for Early Type 2 Diabetes and Obesity Management
Clinical UpdatesGLP-1 receptor agonistobesity

Orforglipron: A Promising Oral Small-Molecule GLP-1 Receptor Agonist for Early Type 2 Diabetes and Obesity Management

By MedXY|Oct 8, 2025

Orforglipron demonstrates significant glycemic control and weight reduction benefits in early type 2 diabetes and obesity, with favorable safety and oral administration convenience.

Efficacy and Safety of cAMP-Biased GLP-1 Receptor Agonist Ecnoglutide Versus Dulaglutide in Type 2 Diabetes: Insights from the EECOH-2 Phase 3 Trial and Broader Clinical Context
Clinical UpdatesdulaglutideEcnoglutide

Efficacy and Safety of cAMP-Biased GLP-1 Receptor Agonist Ecnoglutide Versus Dulaglutide in Type 2 Diabetes: Insights from the EECOH-2 Phase 3 Trial and Broader Clinical Context

By MedXY|Oct 8, 2025

Ecnoglutide, a novel cAMP-biased GLP-1 receptor agonist, demonstrated non-inferior glycemic control and comparable safety to dulaglutide at 52 weeks in type 2 diabetes patients on metformin, offering a promising new treatment option.

Amycretin: A Promising First-in-Class Dual GLP-1 and Amylin Receptor Agonist for Overweight and Obesity
Clinical UpdatesamycretinGLP-1 receptor agonist

Amycretin: A Promising First-in-Class Dual GLP-1 and Amylin Receptor Agonist for Overweight and Obesity

By MedXY|Oct 8, 2025

Amycretin, a novel dual GLP-1 and amylin receptor agonist, demonstrated safety, tolerability, and dose-proportional pharmacokinetics in adults with overweight or obesity, supporting further trials on its weight loss efficacy.

Advancing Obesity Management: Once-Monthly Maridebart Cafraglutide Demonstrates Significant Weight Loss Efficacy
Clinical UpdatesGLP-1 receptor agonistobesity treatment

Advancing Obesity Management: Once-Monthly Maridebart Cafraglutide Demonstrates Significant Weight Loss Efficacy

By MedXY|Oct 6, 2025

Maridebart cafraglutide, a novel once-monthly peptide-antibody conjugate, significantly reduces body weight in individuals with obesity, with and without type 2 diabetes, offering a new therapeutic option based on phase 2 trial results.

Efficacy and Safety of Ecnoglutide, a cAMP-Biased GLP-1 Receptor Agonist, in Weight Management for Overweight and Obese Adults: Insights from a Phase 3 Multicentre Randomised Trial
Diabetes & EndocrinologyEcnoglutideGLP-1 receptor agonist

Efficacy and Safety of Ecnoglutide, a cAMP-Biased GLP-1 Receptor Agonist, in Weight Management for Overweight and Obese Adults: Insights from a Phase 3 Multicentre Randomised Trial

By MedXY|Oct 5, 2025

This review synthesizes evidence from a multicentre, phase 3 trial on ecnoglutide, demonstrating significant and sustained weight loss in overweight/obese adults without diabetes, with a favorable safety profile, supporting its clinical use

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities